Comparative Effectiveness of Lipid-Modifying Agents [Internet]
Article 2009 en
Authors
MS
Mukul Sharma
MA
Mohammed Ansari
KS
Karla Soares‐Weiser
Abstract
1 min read
This evidence report was commissioned by the Agency for Healthcare Research and Quality (AHRQ) to address the following key questions: Key Question 1. For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose statin monotherapy? Key Question 2. Do these regimens differ in reaching LDL targets (or other surrogate markers), short-term side effects, tolerability, and/or adherence? Key Question 3. Compared with higher dose statins and to one another, do combination regimens differ in benefits and harms within subgroups of patients?
Kari A. Mäkelä, Jari Jokelainen, Ville Stenbäck, Juha Auvinen, Paul M Ridker, Mikko P. Tulppo, Juhani Leppäluoto, Sirkka Keinänen‐Kiukaanniemi, Karl‐Heinz Herzig
Marco Alings, Olivier Descamps, B. Guillon, Margrét Leósdóttir, Aldo Maggioni, Lluís Recasens, Walter S. Speidl, Rosario V. Tripodi, Ulf Landmesser, Alberico L. Catapano, Angela Pirillo
Eeva Sliz, Johannes Kettunen, Michael V. Holmes, Clare Oliver‐Williams, Charles Boachie, Qin Wang, Minna Männikkö, Sylvain Sebért, Robin Walters, Kuang Lin, Iona Y. Millwood, Robert B. Clarke, Liming Li, Naomi Rankin, Paul Welsh, Christian Delles, J. Wouter Jukema, Stella Trompet, Ian Ford, Markus Perola, Veikko Salomaa, Paul M Ridker, Zhengming Chen, Debbie A. Lawlor,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.